Quest Diagnostics Incorporated’s Stock Price Soars to $157.47, Marking a Positive Leap of 6.85%

Quest Diagnostics Incorporated (DGX)

157.47 USD +10.10 (+6.85%) Volume: 2.04M

Quest Diagnostics Incorporated’s stock price surged to 157.47 USD, witnessing a remarkable trading session growth of +6.85%. With a trading volume of 2.04M and an impressive YTD percentage change of +14.21%, DGX’s stock performance continues to capture investor interest.

Latest developments on Quest Diagnostics Incorporated

Quest Diagnostics has seen a surge in stock price today after beating quarterly results estimates on the back of strong demand for diagnostic tests. The company’s third-quarter earnings and revenue surpassed expectations, leading to a rise in its stock price. Quest Diagnostics reported a profit increase and updated its guidance for the full year 2024, showcasing its thriving performance in the current market. With new customer wins and expectations for earnings growth in 2025, Quest Diagnostics is poised for continued success in the healthcare industry.

Quest Diagnostics Incorporated on Smartkarma

Analysts on Smartkarma, such as Baptista Research, are bullish on Quest Diagnostics following the company’s recent financial results. According to Baptista Research‘s reports, Quest Diagnostics saw a 2.5% increase in total revenues, with base business revenues growing by nearly 4%. The company’s expansion of new physician and hospital customers, along with an improved test mix, contributed to this growth. Analysts are optimistic about the company’s performance, especially with the acquisition of Canadian lab provider LifeLabs potentially being a game-changer for Quest Diagnostics.

Furthermore, Baptista Research‘s analysis highlights Quest Diagnostics‘ strengthening revenue growth across core services. The company delivered nearly 6% base business revenue growth in Q1, showcasing its ability to maintain a strong commercial focus on physicians and hospitals. Quest Diagnostics‘ continued investment in automation and artificial intelligence, along with a reevaluation of guidance for the full year, has also been positively received by analysts. With a significant focus on physicians and hospitals, coupled with broad health plan access, Quest Diagnostics is well-positioned to drive new customer growth and sustain high rates of health care utilization, according to the research reports.

A look at Quest Diagnostics Incorporated Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics, a company that provides diagnostic testing services, has received positive Smart Scores across various factors. With a high score in Dividend and Value, the company is seen as a reliable investment option with strong potential for returns. Additionally, its Momentum score suggests that Quest Diagnostics is gaining traction in the market, making it a promising choice for investors looking for growth opportunities.

While Quest Diagnostics has received lower scores in Growth and Resilience, the overall outlook for the company remains positive. With a solid foundation in providing diagnostic testing and services, Quest Diagnostics is well-positioned to continue its growth trajectory in the long term. Investors may find value in this company as it maintains a strong presence in the healthcare industry.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma